{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:52:55Z","timestamp":1789912375287,"version":"4.0.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s40265-018-0948-9","type":"journal-article","created":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T08:21:05Z","timestamp":1532074865000},"page":"1145-1156","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Vismodegib: A Review in Advanced Basal Cell Carcinoma"],"prefix":"10.1007","volume":"78","author":[{"given":"James E.","family":"Frampton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Basset-S\u00e9guin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,20]]},"reference":[{"issue":"1","key":"948_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s13671-014-0069-y","volume":"3","author":"SV Mohan","year":"2014","unstructured":"Mohan SV, Chang ALS. Advanced basal cell carcinoma: epidemiology and therapeutic innovations. Curr Dermatol Rep. 2014;3(1):40\u20135.","journal-title":"Curr Dermatol Rep."},{"key":"948_CR2","unstructured":"Lewin JM, Carucci JA. Advances in the management of basal cell carcinoma. F1000Prime Rep. 2015; 7:53."},{"key":"948_CR3","unstructured":"Bichakjian CK, Olencki T, Aasi SZ, et al. Basal cell skin cancer, Version 1.2018 \u2013 September 18, 2017, NCCN Clinical Practice Guidelines in Oncology. https:\/\/www.nccn.org . Accessed 6 Jul 2018."},{"key":"948_CR4","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s12094-014-1272-9","volume":"17","author":"S Puig","year":"2015","unstructured":"Puig S, Berrocal A. Management of high-risk and advanced basal cell carcinoma. Clin Transl Oncol. 2015;17:497\u2013503.","journal-title":"Clin Transl Oncol"},{"key":"948_CR5","first-page":"129","volume":"9","author":"LA Fecher","year":"2015","unstructured":"Fecher LA, Sharfman WH. Advanced basal cell carcinoma, the hedgehog pathway, and treatment options \u2013 role of smoothened inhibitors. Biologics. 2015;9:129\u201340.","journal-title":"Biologics."},{"key":"948_CR6","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s11864-013-0233-9","volume":"14","author":"LA Fecher","year":"2013","unstructured":"Fecher LA. Systemic therapy for inoperable and metastatic basal cell cancer. Curr Treat Options Oncol. 2013;14:237\u201348.","journal-title":"Curr Treat Options Oncol"},{"key":"948_CR7","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/nrc2503","volume":"8","author":"EH Epstein","year":"2008","unstructured":"Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 2008;8:743\u201354.","journal-title":"Nat Rev Cancer"},{"key":"948_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s13555-013-0019-9","volume":"3","author":"CL Cowey","year":"2013","unstructured":"Cowey CL. Targeted therapy for advanced basal-cell carcinoma: vismodegib and beyond. Dermatol Ther (Heidelb). 2013;3:17\u201331.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"2","key":"948_CR9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40257-017-0319-4","volume":"19","author":"R Danhof","year":"2017","unstructured":"Danhof R, Lewis K, Brown M. Small molecule inhibitors of the Hedgehog pathway in the treatment of basal cell carcinoma of the skin. Am J Clin Derm. 2017;19(2):195\u2013207.","journal-title":"Am J Clin Derm."},{"key":"948_CR10","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/nrm3598","volume":"14","author":"J Briscoe","year":"2013","unstructured":"Briscoe J, Th\u00e9rond PP. The mechanisms of Hedgehog signalling and its roles in development and disease. Nat Rev Mol Cell Biol. 2013;14:416\u201329.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"948_CR11","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1242\/dev.083691","volume":"141","author":"R Petrova","year":"2014","unstructured":"Petrova R, Joyner AL. Roles for Hedgehog signaling in adult organ homeostasis and repair. Development. 2014;141:3445\u201357.","journal-title":"Development."},{"key":"948_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12943-016-0522-6","volume":"15","author":"A Hanna","year":"2016","unstructured":"Hanna A, Shevde LA. Hedgehog signaling: modulation of cancer properies and tumor mircroenvironment. Mol Cancer. 2016;15:35.","journal-title":"Mol Cancer."},{"key":"948_CR13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1750-1172-3-32","volume":"3","author":"Muzio L Lo","year":"2008","unstructured":"Lo Muzio L. Nevoid basal cell carcinoma syndrome (Gorlin syndrome). Orphanet J Rare Dis. 2008;3:32.","journal-title":"Orphanet J Rare Dis."},{"issue":"11","key":"948_CR14","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.2165\/11209590-000000000-00000","volume":"72","author":"GM Keating","year":"2012","unstructured":"Keating GM. Vismodegib: in locally advanced or metastatic basal cell carcinoma. Drugs. 2012;72(11):1535\u201341.","journal-title":"Drugs."},{"key":"948_CR15","unstructured":"Roche Registration Ltd. Erivedge 150 mg hard capsules: EU summary of product characteristics. 2016. http:\/\/www.ema.europa.eu . Accessed 6 Jul 2018."},{"key":"948_CR16","unstructured":"Genentech Inc. ERIVEDGE\u00ae (vismodegib) capsule for oral use: US prescribing information. 2012. https:\/\/www.accessdata.fda.gov . Accessed 6 Jul 2018."},{"issue":"8","key":"948_CR17","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1158\/1078-0432.CCR-10-2745","volume":"17","author":"PM LoRusso","year":"2011","unstructured":"LoRusso PM, Rudin CM, Reddy JC, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17(8):2502\u201311.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"948_CR18","doi-asserted-by":"publisher","first-page":"5576","DOI":"10.1016\/j.bmcl.2009.08.049","volume":"19","author":"KD Robarge","year":"2009","unstructured":"Robarge KD, Brunton SA, Castanedo GM, et al. GDC-0449-a potent inhibitor of the hedgehog pathway. Bioorg Med Chem Lett. 2009;19(19):5576\u201381.","journal-title":"Bioorg Med Chem Lett"},{"issue":"12","key":"948_CR19","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1056\/NEJMoa0905360","volume":"361","author":"DD Hoff Von","year":"2009","unstructured":"Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361(12):1164\u201372.","journal-title":"N Engl J Med"},{"issue":"6","key":"948_CR20","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.molonc.2014.05.004","volume":"8","author":"FH Groenendijk","year":"2014","unstructured":"Groenendijk FH, Bernards R. Drug resistance to targeted therapies: d\u00e9j\u00e0 vu all over again. Mol Oncol. 2014;8(6):1067\u201383.","journal-title":"Mol Oncol."},{"issue":"15 Suppl","key":"948_CR21","doi-asserted-by":"publisher","first-page":"9562","DOI":"10.1200\/JCO.2016.34.15_suppl.9562","volume":"34","author":"N Basset-S\u00e9guin","year":"2016","unstructured":"Basset-S\u00e9guin N, Sharpe H, Poulalhon N, et al. Resistances to vismodegibs in a French case series of 207 patients with locally advanced basal cell carcinoma [abstract no. 9562]. J Clin Oncol. 2016;34(15 Suppl):9562.","journal-title":"J Clin Oncol."},{"issue":"3","key":"948_CR22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ccell.2015.02.001","volume":"27","author":"HJ Sharpe","year":"2015","unstructured":"Sharpe HJ, Pau G, Dijkgraaf GJ, et al. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell. 2015;27(3):327\u201341.","journal-title":"Cancer Cell"},{"issue":"11","key":"948_CR23","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1001\/archdermatol.2012.2354","volume":"148","author":"ALS Chang","year":"2012","unstructured":"Chang ALS, Oro AE. Initial assessment of tumor regrowth after vismodegib in advanced basal cell carcinoma. Arch Dermatol. 2012;148(11):1324\u20135.","journal-title":"Arch Dermatol"},{"issue":"3","key":"948_CR24","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.ccell.2015.02.002","volume":"27","author":"SX Atwood","year":"2015","unstructured":"Atwood SX, Sarin KY, Whitson RJ, et al. Smoothened variants explain the majority of drug resistance in basal cell carcinoma. Cancer Cell. 2015;27(3):342\u201353.","journal-title":"Cancer Cell"},{"issue":"2","key":"948_CR25","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.molonc.2014.09.003","volume":"9","author":"S Pricl","year":"2015","unstructured":"Pricl S, Cortelazzi B, Dal Col V, et al. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma. Mol Oncol. 2015;9(2):389\u201397.","journal-title":"Mol Oncol."},{"issue":"8","key":"948_CR26","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1158\/1078-0432.CCR-10-2736","volume":"17","author":"RA Graham","year":"2011","unstructured":"Graham RA, Lum BL, Cheeti S, et al. Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clin Cancer Res. 2011;17(8):2512\u201320.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"948_CR27","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1111\/j.1365-2125.2012.04281.x","volume":"74","author":"RA Graham","year":"2012","unstructured":"Graham RA, Hop CE, Borin MT, et al. Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects. Br J Clin Pharmacol. 2012;74(5):788\u201396.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"948_CR28","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1124\/dmd.111.039339","volume":"39","author":"RA Graham","year":"2011","unstructured":"Graham RA, Lum BL, Morrison G, et al. A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry. Drug Metab Dispos. 2011;39(8):1460\u20137.","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"948_CR29","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1158\/1078-0432.CCR-12-3829","volume":"19","author":"MR Sharma","year":"2013","unstructured":"Sharma MR, Karrison TG, Kell B, et al. Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res. 2013;19(11):3059\u201367.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"948_CR30","doi-asserted-by":"publisher","first-page":"5774","DOI":"10.1158\/1078-0432.CCR-11-0972","volume":"17","author":"PM LoRusso","year":"2011","unstructured":"LoRusso PM, Jimeno A, Dy G, et al. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17(17):5774\u201382.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"948_CR31","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1002\/psp4.12039","volume":"4","author":"T Lu","year":"2015","unstructured":"Lu T, Wang B, Gao Y, et al. Semi-mechanism-based population pharmacokinetic modeling of the Hedgehog pathway inhibitor vismodegib. CPT Pharm Syst Pharmacol. 2015;4(11):680\u20139.","journal-title":"CPT Pharm Syst Pharmacol."},{"issue":"1","key":"948_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00280-017-3315-8","volume":"80","author":"GK Abou-Alfa","year":"2017","unstructured":"Abou-Alfa GK, Lewis LD, LoRusso P, et al. Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment. Cancer Chemother Pharmacol. 2017;80(1):29\u201336.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"948_CR33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00280-016-3020-z","volume":"78","author":"V Malhi","year":"2016","unstructured":"Malhi V, Colburn D, Williams SJ, et al. A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein\/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib. Cancer Chemother Pharmacol. 2016;78(1):41\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"23","key":"948_CR34","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","volume":"366","author":"A Sekulic","year":"2012","unstructured":"Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171\u20139.","journal-title":"N Engl J Med"},{"issue":"6","key":"948_CR35","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.jaad.2015.03.021","volume":"72","author":"A Sekulic","year":"2015","unstructured":"Sekulic A, Migden MR, Lewis K, et al. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015;72(6):1021\u20131026.e8.","journal-title":"J Am Acad Dermatol."},{"issue":"1","key":"948_CR36","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s12885-017-3286-5","volume":"17","author":"A Sekulic","year":"2017","unstructured":"Sekulic A, Migden MR, Basset-S\u00e9guin N, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017;17(1):332.","journal-title":"BMC Cancer."},{"issue":"8","key":"948_CR37","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1634\/theoncologist.2014-0003","volume":"19","author":"B Dr\u00e9no","year":"2014","unstructured":"Dr\u00e9no B, Basset-S\u00e9guin N, Caro I, et al. Clinical benefit assessment of vismodegib therapy in patients with advanced basal cell carcinoma. Oncologist. 2014;19(8):790\u20136.","journal-title":"Oncologist."},{"issue":"6","key":"948_CR38","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S1470-2045(15)70198-1","volume":"16","author":"N Basset-S\u00e9guin","year":"2015","unstructured":"Basset-S\u00e9guin N, Hauschild A, Grob JJ, et al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol. 2015;16(6):729\u201336.","journal-title":"Lancet Oncol."},{"issue":"15 Suppl","key":"948_CR39","doi-asserted-by":"publisher","first-page":"9532","DOI":"10.1200\/JCO.2016.34.15_suppl.9532","volume":"34","author":"J Hansson","year":"2016","unstructured":"Hansson J, Hauschild A, Kunstfeld R, et al. Vismodegib (VISMO), a hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study primary analysis in 1215 patients (pts) [abstract no. 9532]. J Clin Oncol. 2016;34(15 Suppl):9532.","journal-title":"J Clin Oncol."},{"issue":"15 Suppl","key":"948_CR40","doi-asserted-by":"crossref","first-page":"9024","DOI":"10.1200\/jco.2015.33.15_suppl.9024","volume":"33","author":"R Dummer","year":"2015","unstructured":"Dummer R, Basset-S\u00e9guin N, Hansson J, et al. Impact of treatment breaks on vismodegib patient outcomes: exploratory analysis of the STEVIE study [abstract no. 9024]. J Clin Oncol. 2015;33(15 Suppl):9024.","journal-title":"J Clin Oncol."},{"key":"948_CR41","doi-asserted-by":"crossref","unstructured":"Basset-S\u00e9guin N, Hansson J, Kunstfeld R, et al. Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial [oral presentation]. In: 25th EADV Congress; 2016.","DOI":"10.1016\/j.ejca.2017.08.022"},{"issue":"5 Suppl 1","key":"948_CR42","first-page":"AB193","volume":"74","author":"J-J Grob","year":"2016","unstructured":"Grob J-J, Bartley K, Kuntsfeld R, et al. Assessment of quality of life (QoL) using Skindex-16 in patients (pts) with locally advanced basal cell carcinoma (laBCC) treated with vismodegib (VISMO) in the STEVIE study [abstract no. 3140]. J Am Acad Dermatol. 2016;74(5 Suppl 1):AB193.","journal-title":"J Am Acad Dermatol."},{"key":"948_CR43","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ejca.2017.08.022","volume":"86","author":"N Basset-S\u00e9guin","year":"2017","unstructured":"Basset-S\u00e9guin N, Hauschild A, Kunstfeld R, et al. Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial. Eur J Cancer. 2017;86:334\u201348.","journal-title":"Eur J Cancer"},{"issue":"1","key":"948_CR44","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2013.09.012","volume":"70","author":"AL Chang","year":"2014","unstructured":"Chang AL, Solomon JA, Hainsworth JD, et al. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol. 2014;70(1):60\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 3","key":"948_CR45","doi-asserted-by":"publisher","first-page":"S679","DOI":"10.1016\/S0959-8049(16)31859-7","volume":"51","author":"M Lacouture","year":"2015","unstructured":"Lacouture M, Guillen J, Kudchadkar R, et al. The RegiSONIC Disease Registry Study: safety and effectiveness of vismodegib or surgery as primary treatment in patients with locally advanced basal cell carcinoma [abstract no. 3341]. Eur J Cancer. 2015;51(Suppl 3):S679\u201380.","journal-title":"Eur J Cancer"},{"issue":"5 Suppl 1","key":"948_CR46","first-page":"AB200","volume":"74","author":"ME Lacouture","year":"2016","unstructured":"Lacouture ME, Guillen J, Kudchadkar R, et al. Management of common vismodegib (VISMO)-related adverse events in patients with locally advanced basal cell carcinoma (laBCC): RegiSONIC Disease Registry Study [abstract no. 3514]. J Am Acad Dermatol. 2016;74(5 Suppl 1):AB200.","journal-title":"J Am Acad Dermatol."},{"issue":"1","key":"948_CR47","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13023-016-0506-z","volume":"11","author":"AL Chang","year":"2016","unstructured":"Chang AL, Arron ST, Migden MR, et al. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials. Orphanet J Rare Dis. 2016;11(1):120.","journal-title":"Orphanet J Rare Dis."},{"key":"948_CR48","unstructured":"US National Institutes of Health. ClinicalTrials.gov identifier NCT01604252. 2017. https:\/\/clinicaltrials.gov . Accessed 6 Jul 2018."},{"issue":"15 Suppl","key":"948_CR49","doi-asserted-by":"crossref","first-page":"9013","DOI":"10.1200\/jco.2014.32.15_suppl.9013","volume":"32","author":"A Sekulic","year":"2014","unstructured":"Sekulic A, Migden MR, Basset-S\u00e9guin N, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update (30-month) of the pivotal ERIVANCE BCC study [abstract no. 9013]. J Clin Oncol. 2014;32(15 Suppl):9013.","journal-title":"J Clin Oncol."},{"issue":"10","key":"948_CR50","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1634\/theoncologist.2016-0186","volume":"21","author":"ME Lacouture","year":"2016","unstructured":"Lacouture ME, Dreno B, Ascierto PA, et al. Characterization and management of hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma. Oncologist. 2016;21(10):1218\u201329.","journal-title":"Oncologist."},{"key":"948_CR51","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1016\/j.ejca.2013.03.010","volume":"49","author":"SC Flohil","year":"2013","unstructured":"Flohil SC, van der Leest RJ, Arends LR, et al. Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: a systematic review and meta-analysis. Eur J Cancer. 2013;49:2365\u201375.","journal-title":"Eur J Cancer"},{"issue":"4","key":"948_CR52","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.jaad.2017.03.038","volume":"77","author":"T Bhutani","year":"2017","unstructured":"Bhutani T, Abrouk M, Sima CS, et al. Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib. J Am Acad Dermatol. 2017;77(4):713\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 3","key":"948_CR53","doi-asserted-by":"publisher","first-page":"S675","DOI":"10.1016\/S0959-8049(16)31850-0","volume":"51","author":"M Lacouture","year":"2015","unstructured":"Lacouture M, Guillen J, Kudchadkar R, et al. Real-world treatment of vismodegib (VISMO)-related adverse events (AEs) in patients with locally advanced basal cell carcinoma: report from the RegiSONIC Disease Registry Study [abstract no. 3332]. Eur J Cancer. 2015;51(Suppl 3):S675.","journal-title":"Eur J Cancer"},{"issue":"1","key":"948_CR54","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s40268-016-0168-2","volume":"17","author":"BJ Edwards","year":"2017","unstructured":"Edwards BJ, Raisch DW, Saraykar SS, et al. Hepatotoxicity with vismodegib: an MD Anderson Cancer Center and research on adverse drug events and reports project. Drugs R D. 2017;17(1):211\u20138.","journal-title":"Drugs R D."},{"key":"948_CR55","unstructured":"Roche Products (New Zealand) Limited. Erivedge 150 mg hard capsules: New Zealand data sheet. http:\/\/www.medsafe.govt.nz . Accessed 29 June 2018."},{"key":"948_CR56","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2147\/CCID.S101330","volume":"10","author":"Z Apalla","year":"2017","unstructured":"Apalla Z, Papageorgiou C, Lallas A, et al. Spotlight on vismodegib in the treatment of basal cell carcinoma: an evidence-based review of its place in therapy. Clin Cosmet Investig Dermatol. 2017;10:171\u20137.","journal-title":"Clin Cosmet Investig Dermatol."},{"issue":"3","key":"948_CR57","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1684\/ejd.2014.2271","volume":"24","author":"M Trakatelli","year":"2014","unstructured":"Trakatelli M, Morton C, Nagore E, et al. Update of the European guidelines for basal cell carcinoma management. Eur J Dermatol. 2014;24(3):312\u201329.","journal-title":"Eur J Dermatol"},{"key":"948_CR58","unstructured":"Curis Inc. Curis announces full approval of Roche\u2019s Erivedge\u00ae in the European Union [media release]. 28 Nov 2016. http:\/\/investors.curis.com ."},{"key":"948_CR59","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.ejca.2013.12.013","volume":"50","author":"M McCusker","year":"2014","unstructured":"McCusker M, Basset-S\u00e9guin N, Dummer R, et al. Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease. Eur J Cancer. 2014;50:774\u201383.","journal-title":"Eur J Cancer"},{"issue":"15 Suppl","key":"948_CR60","doi-asserted-by":"publisher","first-page":"9535","DOI":"10.1200\/JCO.2017.35.15_suppl.9535","volume":"35","author":"F Herms","year":"2017","unstructured":"Herms F, Luc H, Bagot M, et al. Follow-up of patients with complete remission of locally advanced basal cell carcinoma treated with vismodegib after treatment discontinuation: a retrospective multicentric French study [abstract no. 9535]. J Clin Oncol. 2017;35(15 Suppl):9535.","journal-title":"J Clin Oncol."},{"issue":"5","key":"948_CR61","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1111\/jdv.12526","volume":"29","author":"C Saintes","year":"2015","unstructured":"Saintes C, Saint-Jean M, Brocard A, et al. Development of squamous cell carcinoma into basal cell carcinoma under treatment with vismodegib. J Eur Acad Dermatol Venereol. 2015;29(5):1006\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"948_CR62","unstructured":"Basset-Seguin N. HPI resistance mechanisms and how to overcome it [abstract]. In: 13th EADO Congress; 2017."},{"issue":"2","key":"948_CR63","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s11523-016-0418-9","volume":"11","author":"CB Burness","year":"2016","unstructured":"Burness CB, Scott LJ. Sonidegib: a review in locally advanced basal cell carcinoma. Target Oncol. 2016;11(2):239\u201346.","journal-title":"Target Oncol."},{"key":"948_CR64","unstructured":"Gutzmer R, Sondak V, Migden M. Response to hedgehog pathway inhibitor therapy in patients with locally advanced basal cell carcinoma: composite assessments using 2 sets of response criteria [abstract]. In: 24th EADV Congress; 2015."},{"issue":"6","key":"948_CR65","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1158\/1078-0432.CCR-15-1588","volume":"22","author":"C Danial","year":"2016","unstructured":"Danial C, Sarin KY, Oro AE, et al. An investigator-initiated open-label trial of sonidegib in advanced basal cell carcinoma patients resistant to vismodegib. Clin Cancer Res. 2016;22(6):1325\u20139.","journal-title":"Clin Cancer Res"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-018-0948-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0948-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0948-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T23:24:46Z","timestamp":1661642686000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-018-0948-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":65,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["948"],"URL":"https:\/\/doi.org\/10.1007\/s40265-018-0948-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"20 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"James Frampton is a salaried employee of Adis\/Springer, is responsible for the article content and declares no relevant conflicts of interest. Nicole Basset-S\u00e9guin has received grants or has grants pending (Roche, Genentech); has received consulting fees or honoraria (Roche, Novartis, Pierre Fabre, Leo Pharmaceuticals, Galderma); and has received support for study-related travel, manuscript preparation or other purposes (Galderma, Roche, Leo Pharmaceuticals).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}